KPRX Stock Summary and Trading Ideas (Kiora Pharmaceuticals | NASDAQ:KPRX)

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals trades on the NASDAQ stock market under the symbol KPRX.

As of September 4, 2026, KPRX stock price was flat at $2.55 with 4,395 million shares trading.

KPRX has a beta of 1.26, meaning it tends to be more sensitive to market movements. KPRX has a correlation of 0.11 to the broad based SPY ETF.

KPRX has a market cap of $11.28 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, KPRX traded as high as $8.98 and as low as $1.76.

The top ETF exchange traded funds that KPRX belongs to (by Net Assets): VXF, DFAC, DCOR.

KPRX has underperformed the market in the last year with a price return of -6.6% while the SPY ETF gained +19.8%. KPRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.0% and -4.1%, respectively, while the SPY returned +2.0% and +0.6%, respectively.

KPRX support price is $2.44 and resistance is $2.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPRX shares will trade within this expected range on the day.